Rüdiger Nave

Summary

Affiliation: Nycomed GmbH
Country: Germany

Publications

  1. pmc Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549)
    Takashi Nonaka
    Teijin Institute for Biomedical Research, Teijin Pharma Limited, 4 3 2 Asahigaoka, Hino, Tokyo 191 8512, Japan
    BMC Pharmacol 7:12. 2007
  2. doi Determination of lung deposition following inhalation of ciclesonide using different bioanalytical procedures
    Rüdiger Nave
    Department of Pharmacometrics Pharmacokinetics, Nycomed GmbH, Byk Gulden Str 2, 78467 Konstanz, Germany
    Bioanalysis 2:807-14. 2010
  3. doi Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide
    Rüdiger Nave
    Department of Pharmacometrics Pharmacokinetics, Nycomed GmbH, Konstanz, Germany
    Clin Pharmacokinet 48:243-52. 2009
  4. pmc In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices
    Ruediger Nave
    DMPK, Nycomed GmbH, Konstanz, Germany
    Respir Res 8:65. 2007
  5. doi Deposition and metabolism of inhaled ciclesonide in the human lung
    R Nave
    Dept of Pharmacometrics, Nycomed GmbH, Byk Gulden Str 2, 78467 Konstanz, Germany
    Eur Respir J 36:1113-9. 2010
  6. ncbi In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices
    Ruediger Nave
    ALTANA Pharma AG, Konstanz, Germany
    Biopharm Drug Dispos 27:197-207. 2006
  7. doi Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy vol
    Ruediger Nave
    Nycomed GmbH, Konstanz, Germany
    Clin Ther 31:2988-99. 2009
  8. ncbi Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects
    Ruediger Nave
    ALTANA Pharma AG, Byk Gulden Str 2, 78467, Konstanz, Germany
    Eur J Clin Pharmacol 61:203-8. 2005
  9. ncbi Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis
    Ruediger Nave
    ALTANA Pharma AG, Byk Gulden Str 2, 78467 Konstanz, Germany
    J Clin Pharmacol 46:461-7. 2006
  10. ncbi Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide
    Shashank Rohatagi
    Sanofi Aventis, Bridgewater, New Jersey 2ALTANA Pharma AG, Konstanz, Germany
    Am J Ther 12:201-9. 2005

Collaborators

  • Stanley Szefler
  • Helgo Magnussen
  • Frank Kanniess
  • Hartmut Derendorf
  • E Mutch
  • Hideyuki Sato
  • Shashank Rohatagi
  • Anton Drollmann
  • Takashi Nonaka
  • Zheming Gu
  • Zuyu Guo
  • Steve Newman
  • Kai Richter
  • Hao Feng
  • Atsuko Kawashimo
  • Yasuhiro Katsuura
  • Nigel McCracken
  • Jinn Wu
  • Xian guo Zhao
  • Dave D W Liu
  • Stanley R Howell
  • Volker W Steinijans
  • Thomas D Bethke
  • Eugen Baumgärtner
  • Andrew Salmon
  • Michael David
  • Kelly Chen
  • Liduo Shen
  • Yongyi Luo
  • S Peter King
  • Yongqing Huang
  • Christina Schemm
  • Christian Biberger
  • Donald Banerji
  • Sireesh Appajosyula
  • Karl Zech

Detail Information

Publications19

  1. pmc Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549)
    Takashi Nonaka
    Teijin Institute for Biomedical Research, Teijin Pharma Limited, 4 3 2 Asahigaoka, Hino, Tokyo 191 8512, Japan
    BMC Pharmacol 7:12. 2007
    ..High performance liquid chromatography with tandem mass spectrometry was used to measure the concentrations of both corticosteroids and metabolites...
  2. doi Determination of lung deposition following inhalation of ciclesonide using different bioanalytical procedures
    Rüdiger Nave
    Department of Pharmacometrics Pharmacokinetics, Nycomed GmbH, Byk Gulden Str 2, 78467 Konstanz, Germany
    Bioanalysis 2:807-14. 2010
    ..The pulmonary bioavailability was more than 60% as assessed for des-CIC in pharmacokinetic studies using HPLC-MS/MS detection as bioanalytical method. Pharmacokinetics in asthmatic patients and healthy subjects are similar...
  3. doi Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide
    Rüdiger Nave
    Department of Pharmacometrics Pharmacokinetics, Nycomed GmbH, Konstanz, Germany
    Clin Pharmacokinet 48:243-52. 2009
    ..The unique pharmacokinetic and pharmacodynamic profile of ciclesonide offers a rationale that supports the favourable risk-benefit profile observed in clinical trials in patients with persistent asthma...
  4. pmc In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices
    Ruediger Nave
    DMPK, Nycomed GmbH, Konstanz, Germany
    Respir Res 8:65. 2007
    ..CIC, a new generation ICS, is hydrolyzed by esterases in the upper and lower airways to its pharmacologically active metabolite desisobutyryl-ciclesonide (des-CIC)...
  5. doi Deposition and metabolism of inhaled ciclesonide in the human lung
    R Nave
    Dept of Pharmacometrics, Nycomed GmbH, Byk Gulden Str 2, 78467 Konstanz, Germany
    Eur Respir J 36:1113-9. 2010
    ..A substantial portion of ciclesonide was already activated to des-CIC at the first time-point of tissue analysis. Activation of ciclesonide and formation of des-CIC fatty acid conjugates was confirmed in vivo in the human lung...
  6. ncbi In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices
    Ruediger Nave
    ALTANA Pharma AG, Konstanz, Germany
    Biopharm Drug Dispos 27:197-207. 2006
    ..Activation and fatty acid esterification in the lung followed by rapid inactivation in the liver may explain the improved safety profile and prolonged anti-inflammatory activity of ciclesonide...
  7. doi Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy vol
    Ruediger Nave
    Nycomed GmbH, Konstanz, Germany
    Clin Ther 31:2988-99. 2009
    ..However, systemic exposure with ciclesonide HFA nasal aerosol (CIC-HFA) developed for the treatment of allergic rhinitis has not been investigated...
  8. ncbi Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects
    Ruediger Nave
    ALTANA Pharma AG, Byk Gulden Str 2, 78467, Konstanz, Germany
    Eur J Clin Pharmacol 61:203-8. 2005
    ..We studied oropharyngeal deposition of ciclesonide, des-CIC, and budesonide...
  9. ncbi Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis
    Ruediger Nave
    ALTANA Pharma AG, Byk Gulden Str 2, 78467 Konstanz, Germany
    J Clin Pharmacol 46:461-7. 2006
    ..Ciclesonide was well tolerated and did not appear to affect serum or urine free cortisol levels. The low systemic exposure and favorable safety profile support the continued clinical development of ciclesonide nasal spray...
  10. ncbi Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide
    Shashank Rohatagi
    Sanofi Aventis, Bridgewater, New Jersey 2ALTANA Pharma AG, Konstanz, Germany
    Am J Ther 12:201-9. 2005
    ..The very low fraction of unbound des-CIC in the systemic circulation suggests minimal systemic exposure of unbound des-CIC, thus suggesting a low potential for systemic adverse effects after administration of inhaled ciclesonide...
  11. ncbi Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation
    Anton Drollmann
    ALTANA Pharma AG, Konstanz, Germany
    Clin Pharmacokinet 45:729-36. 2006
    ..A spacer may be used in combination with the hydrofluoroalkane metered-dose inhaler (HFA-MDI) to maintain inhaled corticosteroid delivery to the lung in patients with poor inhalation technique...
  12. ncbi Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects
    Ruediger Nave
    ALTANA Pharma AG, Konstanz, Germany
    Clin Pharmacokinet 43:479-86. 2004
    ..Ciclesonide is a novel inhaled corticosteroid developed for the treatment of asthma...
  13. pmc Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa
    Hideyuki Sato
    Teijin Institute for Biomedical Research, Teijin Pharma Limited, Asahigaoka, Hino, Tokyo, Japan
    BMC Pharmacol 7:7. 2007
    ..Retention and formation of fatty acid conjugates of des-CIC were also measured in nasal mucosa extracts postadministration of a hypotonic ciclesonide suspension (143-mug single dose)...
  14. ncbi Comparative in vitro metabolism of 14C-ciclesonide in hepatocytes from the mouse, rat, rabbit, dog, and human
    Zheming Gu
    XenoBiotic Laboratories Inc, Plainsboro, NJ, USA
    Am J Ther 14:280-90. 2007
    ....
  15. ncbi The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue
    Elaine Mutch
    Toxicology Unit, Clinical and Laboratory Sciences, The University of Newcastle, Newcastle upon Tyne, UK
    Biochem Pharmacol 73:1657-64. 2007
    ....
  16. ncbi In vitro metabolism of ciclesonide in human nasal epithelial cells
    Hideyuki Sato
    Teijin Institute for Biomedical Research, Teijin Pharma Limited, Hino, Tokyo, Japan
    Biopharm Drug Dispos 28:43-50. 2007
    ..In conclusion, ciclesonide was rapidly converted to des-CIC by carboxylesterases and cholinesterases, and des-CIC underwent reversible fatty acid conjugation in HNEC...
  17. ncbi High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma
    Steve Newman
    Pharmaceutical Profiles, Nottingham, UK
    Respir Med 100:375-84. 2006
    ..To examine the deposition and pharmacokinetics of ciclesonide administered via hydrofluoroalkane-metered dose inhaler (HFA-MDI) in patients with asthma...
  18. ncbi Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma
    Kai Richter
    Pulmonary Research Institute at Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery, Woehrendamm 80, 22927 Grosshansdorf, Germany
    J Clin Pharmacol 45:146-52. 2005
    ..Furthermore, there is little activation of ciclesonide to its active metabolite in the oropharynx, suggesting a decreased likelihood of inhaled ciclesonide-associated oropharyngeal side effects...
  19. ncbi Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective
    Shashank Rohatagi
    Aventis Pharmaceuticals, Bridgewater, NJ 08807 0800, USA
    J Clin Pharmacol 44:37-47. 2004
    ..Currently available inhaled glucocorticoids do not provide the complete pharmacokinetic/pharmacodynamic parameters to optimize RBV, leaving room for improvement in the development of future agents...